ClinicalTrials.gg
CompletedNCT00417807Updated Dec 24, 2010

Imatinib Mesylate in Patients With Refractory Desmoplastic Small Round Cell Tumors

A Phase 1/2 interventional study of Imatinib mesilate in Refractory Desmoplastic Small Round Cell Tumors, sponsored by Novartis Pharmaceuticals. Completed at 8 sites in Italy. Open to participants aged 16 Years and older. Per ClinicalTrials.gov, last updated 2010-12-24.

Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 1/2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
9
Allocation
Non-randomized
Ages
16 Years and older
Sex
All
01

Study summary

An open-label, non-comparative study conducted to investigate the activity and safety of imatinib mesylate in refractory desmoplastic small round cell tumors expressing PDGF-R. Patients will be treated up to 12 months, or to disease progression. Tumor will be evaluated according to Recist criteria

02

Conditions studied

  • Refractory Desmoplastic Small Round Cell Tumors

Keywords

  • refractory desmoplastic small round cell tumors
  • PDGF-R
03

In context

Desmoplastic Small Round Cell Tumor

59 studies on the registry are indexed under Desmoplastic Small Round Cell Tumor; 14 are open to participants now.

This study's enrollment of 9 is below the median of 44 across 47 interventional studies indexed under Desmoplastic Small Round Cell Tumor.

Browse Desmoplastic Small Round Cell Tumor studies →

Lead sponsor

Novartis Pharmaceuticals is the lead sponsor of 2,719 studies on the registry; 222 are open to participants now.

Of its 585 completed or terminated interventional studies of FDA-regulated products, 439 (75%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
16 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Patients > 16 years of age.
  2. documented diagnosis of DSRCT, unresponsive or in no complete remission after any conventional multimodality approach.
  3. Immunohistochemical documentation of activated PDGF-R expression by tumor
  4. At least one measurable site of disease
  5. Performance status 0,1, 2 or 3 ()
  6. Adequate end organ function

Exclusion criteria

Exclusion criteria:

  1. Patient has received any other agents within 28 days of first day of study drug dosing, unless the disease is rapidly progressing.
  2. Patient is \< 5 years free of another primary
  3. Patient with congestive heart failure or myocardial infarction within 6 months of study
  4. Female patients who are pregnant or breast-feeding.
  5. Severe and/or uncontrolled medical disease
  6. Known .
  7. Chronic active hepatitis or cirrhosis
  8. Known diagnosis of (HIV) infection.
  9. Chemotherapy within 4 weeks prior to study entry, unless the disease is rapidly progressing.
  10. Previous radiotherapy to > 25 % of the bone marrow
  11. Major surgery within 2 weeks prior to study entry.

Other protocol defined inclusion/exclusion criteria may apply.

Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
9 participants (actual)

Study arms

  • Experimental
    Gleevec/Glivec

    Drug: Imatinib mesilate

Interventions

06

What researchers measure

Primary outcomes

  1. Overall tumor response rates

    An imaging technique (CT scan or MRI) determined tumor response according to RECIST criteria.

    Time frame: Assessed every 3 months

Secondary outcomes

  1. Explore how Imatinib cooperated with other treatment modatilities

    Recorded survival after treatment and other associated treatment modalities.

    Time frame: Survival data was collected until death

  2. Safety and tolerability

    Time frame: Safety data collected until patients were no longer in study

  3. Conversion rate to surgical resectability

    Assessed actual resectability rate after therapy compared to resectability before therapy.

    Time frame: After best tumor response.

  4. Mutational analysis of molecular targets of imatinib (at any time during the study)

    Time frame: At any time during the study

07

Study locations

8 sites
  • Novartis Investigative Site
    Ivrea, Italy
  • Novartis Investigative Site
    Milano, Italy
  • Novartis Investigative Site
    Napoli, Italy
  • Novartis Investigative Site
    Padova, Italy
  • Novartis Investigative Site
    Ravenna, Italy
  • Novartis Investigative Site
    Rozzano, Italy
  • Novartis Investigative Site
    Torino, Italy
  • Novartis Investigative Stie
    Vatania, Italy
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Aug 2005 and a primary completion of Jun 2009. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 2, 2007
First posted
Jan 4, 2007
Start
Aug 2005
Primary completionActual
Jun 2009
Last update
Dec 24, 2010
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 24, 2010, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00417807
First posted
Jan 4, 2007
Start date
Aug 2005
Primary completion
Jun 2009
Last update
Dec 24, 2010

Study contacts

Novartis Pharmaceuticals
study director · Novartis Pharmeceuticals
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2010. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Imatinib

Start the discussion